A selected record of direct investments, strategic and financial advisory positions, and governance roles.
Clinical-stage, LSE-listed, developing DNA and mRNA-based gene therapies targeting age related diseases and longevity. Lead programs target dog health and human health including MASH, Sarcopemia and Glaucoma.
Invested in the company and acting as Chair of the Board.
AI-powered platform developing next-generation therapeutics for severe allergy and mast cell related diseases, through precision immunotherapy and novel biologic approaches. Developed first-in-class mRNA-tLNP based in vivo CAR-T cell therapy specifically targeting Mast cells.
Invested in pre-seed capital round, acting as an advisor and board member.
Clinical stage venture, spun out of the University of Florida, developing mRNA based personalised cancer immunotherapeutics and combination therapies leveraging AI guided novel tumour antigen discovery platforms.
Acting as an advisor.
Cambridge MA based early-stage venture developing next-generation mRNA-tLNP in vivo gene editing therapeutics, spun out of a major academic institution.
Co-founded the company, invested in pre-seed round.
Arch Venture backed mRNA therapeutics platform. Developed revolutionary microfluidics based "RNA on biochip" manufacturing platform.
Advised on business & corporate development and financing strategy through company acquisition by Medici Therapeutics in December 2025.
Truffle Capital backed, clinical-stage venture (formerly Diaccurate) developing first-in-class precision oncology therapeutics, including a dual node PAM inhibitor and a KIF20A inhibitor across multiple cancer indications. Company entered into a strategic collaboration with Roche.
Advised on business development and financing strategy, acted at Vice Chaiman of the Board.